Asset 2 Conferences
Linding Rune - profile picture

Rune Linding

University of Copenhagen, DK

Dr. Linding completed his Ph.D. at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, followed by postdoctoral training at EMBL. He then jointly trained with professors Tony Pawson and Mike Yaffe at the Lunenfeld at Mount Sinai Hospital in Toronto, Canada, and the Massachusetts Institute of Technology (MIT) in Cambridge, US, respectively. Dr. Linding then established his own laboratory of Cellular & Molecular Logic at the Institute of Cancer Research (ICR) in London, UK, before returning to Denmark to take a position as professor of cellular signal integration at the Technical University of Denmark. In 2014, Dr. Linding moved his laboratory to the Biotech Research and Innovation Centre (BRIC) at University of Copenhagen where he is currently professor of cellular signaling. His research group focuses on big data network biology, exploring biological systems by developing and deploying algorithms aimed to predict cell behavior, in particular looking at cellular signal processing and decision making. A strategic focus is to continue to develop computational tools (such as KinomeXplorer, NetworKIN, and NetPhorest) and to deploy these on genome-scale quantitative data obtained by, for example, mass spectrometry, genomic, and phenotypic screens to understand the principles of how spatio and temporal assembly of mammalian signaling networks transmit and process information at a systems level in order to alter cell behavior. His overarching aim is to advance network medicine by identifying and targeting signaling networks associated with complex diseases. To this end Dr. Linding is currently leading high-level, strategic, multidisciplinary studies of signaling network dynamics driving cancer metastasis in collaboration with other labs at Harvard, Yale, The Jackson Laboratory, Memorial Sloan Kettering Cancer Center, MIT, and BRIC.

Check Rune's publication on Dynamic Rearrangement of Cell States Detected by Systematic Screening of Sequential Anticancer Treatments

Speaker at